Single cell qPCR

Single cell qPCR characterization of ATMP

Lead: RISE – Joakim Håkansson

Involved partners: VERIGRAFT AB, TATAA Biocenter AB

The project aims:

The aim of this project is to develop FACS sorting and single cell gene expression analysis as a method of cell characterization for use as functional assays and quality controls of cell- and tissue engineered ATMPs. In this project, the cells of personalized tissue engineered veins will be characterized and compared with native tissue one year after transplantation.

Examples of tasks and actions:

  • Choosing FACS sorting markers
  • Development and validation of qPCR assays for single cell characterization
  • Comparative analysis of gene expression profile of cells in personalized tissue engineered veins with native vein tissue one-year after transplantation.

Interview with project leader

Hi Joakim Håkansson!

What is the need your project addresses?

Proper quality controls and functional assays are important tools to be able to have detailed control over the molecular characteristics (gene- and protein expression profiles) of the cells in an ATMP to be transplanted to patients. Also, in the research and development of an ATMP, it is vital to investigate safety and functionality of the ATMP after long time in vivo use. For this, the same quality controls and potency assays can be used.

What is your approach to meet the need?

In this project, the cells of a personalized tissue engineered vein will be characterized and compared with those of native vein tissue one year after transplantation. The cells will be dissociated from the tissue, FACS sorted and characterized for the gene expression profile with single-cell qPCR. We have assembled a small and highly skilled project team to do the studies.

How will this improve Sweden´s capabilities within ATMPs?

Although the project uses a specific ATMP as the study model, the technologies used in this project are generic, and could readily be developed and applied towards other ATMPs. We see this project as a pilot, that can be followed by a much wider approach involving other cell types and ATMPs. Customized quality controls and potency assays are important ingredients in evaluating the safety and functionality of ATMPs under development, and this

project will contribute to building Swedish capabilities and establish Sweden as a frontier in the field of regenerative medicine and novel advanced therapies.

For more information please contact Joakim Hakansson